March 6, 2023 06:34 AM ESTUpdated March 9, 06:49 AM
R&D

Cy­to­ki­net­ic­s' heart drug shows pos­i­tive re­sults af­ter FDA re­jec­tion of ear­li­er treat­ment: #ACC23

Lei Lei Wu

News Reporter

NEW OR­LEANS — Less than a week af­ter its heart fail­ure drug was re­ject­ed by the FDA, Cy­to­ki­net­ics is back with da­ta from an­oth­er pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Nu­ra Bio rais­es $68M for clin­i­cal tests of SARM1 in­hibitor to po­ten­tial­ly slow or pre­vent nerve de­gen­er­a­tion

Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets 

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times